1. Oral Anticoagulation in AF

3. Current Gaps in Treatment

4. Use of NOACs in the Real World

5. Misconceptions About NOAC Doses

6. Dose Reduction Criteria for NOACs

7. Aspirin

8. Phase 3 AF Trials of NOACs Trial Baseline Characteristics

9. Risk-Benefit Profile of NOACs vs Warfarin in the Elderly

10. Malignancy and AF Insights From ENGAGE AF-TIMI 48

11. Drug-Drug Interactions

12. Clinical Implications of Inappropriately Using Lower Doses of NOACs

13. Efficacy and Safety of Warfarin

14. Greater Absolute Net Benefit With Edoxaban in Older Patients

15. Reluctance to Use NOAC Based on Lack of Reversal Agent?

16. Reliability of NOACs Based on Real-World Data

17. RE-VERSE AD Prognosis Following Reversal of Dabigatran

18. NOACs in Advanced Kidney Disease

19. Limitations of Registry Data

20. Key Take-Home Messages

21. Abbreviations

22. Abbreviations (cont)